The novel coronavirus SARS-CoV-2 has infected over a hundred million worldwide, resulting in debilitating morbidity, and the death of millions. Because of its widespread and devastating impact, research into SARS-CoV-2 is progressing at an incredibly fast pace. The goal of this session is to present the latest advances in therapeutics and vaccines targeting this virus. Because this is a fast-moving field, speakers will present the most recent advances in their area of therapeutic strategy.
CME credits and/or Certificates of Completion are not provided for this session.
1- Understand how therapeutics targeting immune responses are being used to treat SARS-CoV-2 infections
2- Describe how SARS-CoV-2 affects the vasculature and how to diagnose, manage and prevent vascular complications of implications of infection
3- Facilitate implementation of effective vaccines and therapeutics directed towards SARS-CoV-2 infections and combat vaccine hesitancy
Katrina Traber, MD, PhD: Introduction
Jussi J. Saukkonen, MD: Antiviral Agents for Killing SARS-CoV-2
Philippe R. Bauer, MD, PhD: Correcting Immune Dysfunction and Enhancing Host Defense for Treatment of COVID-19
Belinda Natalia Rivera-Lebron, MD, MS: Hypercoagulability and Vascular Dysfunction
Rhea N. Coler, MSc, PhD: Vaccination - State of the Currently Available Vaccines
Rachel Caskey, MD: Vaccination - Challenges and Opportunities to Scale up an Effective Implementation of Vaccines
Susanne Herold, MD, PhD: Wrap Up
You can save 20% today by joining the ATS. Join more than 16,000 healthcare providers and researchers as a member of the American Thoracic Society today. As an ATS member, you’ll gain access to cutting-edge science, collaboration opportunities, discounts on the annual ATS International Conference, and resources to share with patients. The ATS offers multiple ways to get involved, from Assembly membership to in-person networking opportunities, as well as an online community offered through DocMatter. Join the ATS Today!